University of Illinois students created oPool+, a breakthrough method to mass-produce and test thousands of antibodies.

The discovery and optimization of antibodies, whether through traditional methods or with the assistance of artificial intelligence, necessitates rapid and reliable data generation. Here we introduce ...

The collaboration builds on the internal strengths of Bayer in antibody design, synthesis and machine learning, complementing ...

Antibody production can slow research to a crawl. As senior vice president of Biointron, Lei Shi works with scientists around the globe to optimize and expedite their antibody projects, from start to ...

A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ADC Manufacturing for Next-Gen Oncology, reveals an advancement in antibody-d ...

The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...

For decades, antibodies have been one of the crown jewels of modern medicine—powerful molecules that can neutralize viruses, tame autoimmune diseases, and revolutionize cancer care. Yet despite their ...

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

The oPool+ display platform combines technologies to make and test large numbers of antibodies at once. Illinois researchers analyzed how antibodies bind to the influenza protein hemagglutinin.

The rapid advancements in cancer immunotherapy have positioned bispecific antibodies (BsAbs) and T-cell engagers (TCEs) as transformative therapeutic strategies. However, the development of these ...